A Translational Study of Single Agent Olaparib in the Treatment of Advanced Oesophagogastric Cancer

Sponsor
Royal Marsden NHS Foundation Trust
Study ID
NCT03829345
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Olaparib — DRUG
    Patients will be administered olaparib orally twice daily (BD) at 300mg continuously for each 28 day cycle.

Study Details

SOlar is a multi-centre phase II clinical trial of single agent olaparib in advanced oesophagogastric cancer.

Key Dates

Start date
Jul 2, 2019
Status verified
Jul 2019
Primary completion
Feb 14, 2021
Completion
Feb 14, 2022

Study Design

Enrollment
54 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Olaparaib
    Olaparib will be given 300mg bd for a 28 day cycle.

Primary Outcome Measure

Disease Control Rate [ Time Frame: 8 weeks from initiation of study drug ]

Central Contacts

Related Studies